For parents, healthcare professionals and retailers in the UK, innovation in infant feeding is moving beyond basic nutrition. Brands are increasingly competing through human milk research, HMOs, probiotics, prebiotics, alternative protein sources, plant-based DHA, ingredient transparency and products designed for specific nutritional needs.
The strongest names to watch include Aptamil, Kendamil, SMA and HiPP, with each taking a different approach to product development and nutrition science.
Understand what companies are investing in and what customers are willing to buy. Download Sample: https://www.towardshealthcare.com/download-sample/6437
What Makes an Infant Nutrition Brand Innovative?
Innovation can include:
- Human milk oligosaccharides or HMOs
- Probiotic and prebiotic combinations
- New protein sources
- Goat-milk formulations
- Plant-based DHA
- Reduced or reformulated ingredients
- Products for specific nutritional needs
- Research into gut microbiome development
- Sustainable ingredient sourcing
- Improved feeding convenience
For UK families, innovation also needs to work within strict infant-feeding regulations and established clinical nutrition guidance.
Aptamil: Strong Research-Led Infant Nutrition
Aptamil, owned by Danone through its specialised nutrition business, is one of the most established infant-nutrition brands in the UK.
Danone has more than 125 years of specialised-nutrition experience and more than 50 years of breastmilk research. Its specialised-nutrition business generated €9.3 billion in 2025 sales, and Danone identifies itself as the global No. 2 in early-life nutrition.
Aptamil’s innovation strategy is strongly research-led, focusing on early-life nutrition and formulations inspired by the composition and functions of human milk.
Why consider Aptamil?
Pros
- Extensive early-life nutrition research
- Strong UK presence
- Broad infant and follow-on nutrition portfolio
- Significant scientific investment through Danone
- Strong healthcare-professional engagement
- Access to Danone’s global specialised-nutrition research infrastructure
Cons
- Premium and specialised products can be more expensive
- Product claims need to be interpreted within UK regulatory requirements
- Parents may find different Aptamil formulations difficult to distinguish
- Innovation does not mean every formulation is clinically superior for every infant
For investors and healthcare professionals, Aptamil’s key strength is its combination of brand scale, scientific research and specialised nutrition expertise.
Kendamil: UK-Made Formulation Innovation
Kendamil has taken a different approach by emphasizing whole milk, goat milk, ingredient sourcing and formulation simplicity.
Its Goat First Infant Milk uses whole A2 goat milk and goat whey, contains GOS and HMOs, uses marine algae as a source of DHA and is free from palm oil, fish oil and soy.
Kendamil’s UK product page lists its 800g Goat First Infant Milk at £21, although prices can change by retailer and over time.
The brand describes itself as the UK’s No.1 goat formula. UK Competition and Markets Authority analysis also shows Kendamil gaining significant share in several categories. In the first 11 months of 2024, Kendal Nutricare’s share in the comfort-formula category reached 10% to 20%, replacing Nestlé as the second-largest manufacturer in that category. Its growing-up milk share also reached 10% to 20%, ahead of SMA.
Why consider Kendamil?
Pros
- Strong UK identity
- Whole goat-milk formulation
- Plant-based DHA from marine algae
- No palm oil in its goat formula
- Vegetarian positioning
- Strong ingredient-transparency message
- Rapid growth in several UK categories
Cons
- Goat formula is not appropriate for every infant
- Ingredient differences should not automatically be interpreted as clinical superiority
- Premium positioning can increase household costs
- Parents should seek professional advice for infants with suspected allergies or medical nutritional needs
Kendamil’s biggest differentiator is its combination of ingredient positioning, UK sourcing and alternative milk formulation.
SMA: Established Scientific and Nutritional Expertise
SMA Nutrition, associated with Nestlé, remains an important infant-feeding brand in the UK.
Nestlé’s 2025 reporting highlights continued investment in early-life nutrition research, particularly around probiotics, HMOs, gut microbiome development and immunity.
Nestlé’s NAN Sinergity combines six HMOs and two probiotic strains, and the company plans to expand the product to 50 countries by the end of 2026.
Why consider SMA/Nestlé?
Pros
- Large scientific research base
- Strong expertise in infant nutrition
- Focus on HMOs and probiotics
- Global R&D capabilities
- Strong healthcare-professional engagement
- Broad nutritional-science infrastructure
Cons
- Some of the newest innovations are associated with the wider Nestlé NAN portfolio rather than UK SMA products specifically
- Product availability differs by country
- Parents may find scientific ingredient claims difficult to compare
- Premium formulations can cost more
Nestlé’s strength is its ability to combine large-scale R&D, microbiome research and nutritional science with commercial infant-feeding brands.
HiPP: Organic and Ingredient-Focused Innovation
HiPP takes a different route, emphasizing organic ingredients, sustainable agriculture and carefully controlled formulations.
Its differentiation is less about adding increasingly complex functional ingredients and more about organic sourcing, ingredient quality and environmental positioning.
UK competition data indicates that HiPP remains active across specialist infant-formula categories, although its revenue share varies considerably by product category.
Why consider HiPP?
Pros
- Strong organic positioning
- Focus on ingredient sourcing
- Established European infant-nutrition expertise
- Strong sustainability proposition
- Clear differentiation from conventional formulas
Cons
- Organic positioning does not automatically mean superior clinical outcomes
- Generally premium positioning
- Less differentiated in some advanced functional-nutrition categories
- Product availability can vary
HiPP is particularly interesting for consumers who prioritize organic sourcing, ingredient transparency and sustainability.
How Do the Leading Brands Compare?
| Brand | Parent company | Key innovation | Latest relevant data | Main strength |
|---|---|---|---|---|
| Aptamil | Danone | Breastmilk research and specialised nutrition | Danone specialised nutrition: €9.3B sales in 2025 | Research and early-life science |
| Kendamil | Kendal Nutricare | Whole goat milk, A2 protein, plant-based DHA | UK goat formula listed at £21/800g | Ingredient and formulation differentiation |
| SMA | Nestlé | HMOs, probiotics and microbiome research | NAN Sinergity planned for 50 countries by end-2026 | Scientific R&D scale |
| HiPP | HiPP | Organic ingredients and sustainable sourcing | Private company | Organic and sustainability positioning |
The company figures are not directly comparable, because Danone reports specialised-nutrition sales while Kendamil and HiPP are not publicly reporting equivalent figures.
Real Data of Parents in the UK and Beyond the UK
The UK opportunity needs to be viewed alongside actual infant-feeding behavior.
In the 2024 Infant Feeding Survey for England, 86% of mothers initiated breastfeeding, while 15% fed their baby infant formula only from birth. When leaving hospital, 54% were feeding only breast milk, 25% were using both breast milk and infant formula, and 22% were using only infant formula.
At six months, 58% of mothers were still breastfeeding, while 26% were exclusively breastfeeding. Among mothers who had initially breastfed, 68% continued to breastfeed for at least six months.
This means infant-formula demand exists alongside breastfeeding, particularly among combination-feeding families and families using formula exclusively.
UK Parent and Infant-Feeding Statistics
| Indicator | UK/England data |
|---|---|
| Mothers initiating breastfeeding | 86% |
| Breastfeeding at 2 weeks | 80% |
| Breastfeeding at 6 weeks | 71% |
| Breastfeeding at 6 months | 58% |
| Exclusive breastfeeding at 6 months | 26% |
| Planned breast milk only | 55% |
| Planned combination feeding | 23% |
| Planned formula only | 14% |
| Formula only from birth | 15% |
| Formula only after leaving hospital | 22% |
| Breast milk + formula after leaving hospital | 25% |
Contact us for more: https://www.towardshealthcare.com/contact-us
The latest routine England data also shows breastfeeding at 6 to 8 weeks reached 55.6% in 2024 to 2025, up from 52.7% in 2023 to 2024.
Beyond the UK
Danone’s 2025 specialised-nutrition performance shows that demand and growth extend well beyond Britain:
- Europe: €3.22B, +2.1%
- North America: €464M, +6.6%
- China, North Asia & Oceania: €2.77B, +13.2%
- AMEA & Latin America: €2.83B, +8.1%
- Global specialised nutrition: €9.3B, +7.4%
The strongest 2025 growth came from China, North Asia & Oceania, followed by AMEA and Latin America.
This makes the UK important for established brands such as Aptamil, Kendamil, SMA and HiPP, while Asia-Pacific and emerging regions offer significant growth opportunities for specialised and innovative nutrition products.
Who Are the Actual Buyers?
Infant-feeding purchasing involves several groups:
- Parents and caregivers: primary purchasers
- Midwives: influential during early feeding decisions
- Health visitors: provide feeding guidance
- Paediatricians: important for infants with specific nutritional needs
- Pharmacists: influential for specialist formulas
- NHS hospitals and maternity services: important for clinical nutrition and feeding protocols
- Supermarkets and pharmacies: major retail channels
- Online retailers: increasingly important for repeat purchases
The buyer is therefore not always the person who makes the clinical recommendation.
What Are Parents and Healthcare Professionals Looking For?
The main requirements include:
- Nutritionally complete products
- Easy preparation
- Good tolerance
- Clear ingredient information
- Trusted scientific evidence
- Specialist options when clinically required
- Affordable pricing
- Reliable availability
- Convenient packaging
- Sustainable sourcing
Parents are also increasingly interested in HMOs, probiotics, goat milk, organic ingredients and plant-based DHA, although these features should not automatically be interpreted as clinically superior.
What Companies Should Focus On
Leading infant-nutrition companies should focus on:
- Stronger clinical evidence behind functional ingredients
- Transparent communication of nutritional benefits
- Microbiome and HMO research
- Better specialist nutrition
- Affordable premium formulations
- Sustainable ingredient sourcing
- Responsible innovation
- Easier-to-understand product differentiation
- Stronger healthcare-professional education
The biggest opportunity is to connect scientific innovation with clear, evidence-based benefits that parents and healthcare professionals can understand.
How Towards Healthcare Can Help You?
Towards Healthcare Research & Consulting can help infant-nutrition companies and investors track:
- Competitor product innovation
- Infant-nutrition R&D
- Company sales and revenue
- Ingredient innovation
- HMO and probiotic developments
- Consumer and buyer identification
- Regional opportunities
- Healthcare-professional preferences
- Pricing and affordability
- New product launches
- Competitor investments and strategic moves
The objective is to connect nutrition science, product innovation, consumer needs and company performance to identify where the strongest opportunities are emerging.
Connect with us for complete guidance or further enquiry at [email protected]
Europe Region – +44 778 256 0738
North America Region – +1 8044 4193 44
APAC Region: +91 9356 9282 04
Visit Our Website: https://www.towardshealthcare.com
Find us on social platforms: LinkedIn | Twitter | Instagram | Medium